Trump asks drug makers voluntarily to reduce US prices, but do they comply with?

Pharmaceutical companies were waiting for President Donald Trump’s announcement nervously Pharmaceutical definitionsBut instead, the “Better of Fear” Executive Order signed on Monday. according to New York TimesTrump, in pharmaceutical companies that voluntarily reduce US prices.

Although there is no real legal authority to age this, the executive matter said that if the drug makers do not reduce the American prices, the Trump administration will consider imposing regulations or importing medicines from other countries.

On Sunday, Trump stated in a Social truth It will use the “most preferred country policy”, as the United States will pay the same price of the nation that pays the lowest price. This caused the high pharmaceutical stocks on Monday morning.

“I am not knocking on the pharmaceutical companies,” Trump said at the Times. “I really offer countries more than pharmaceutical companies.”

Time in mind, the executive order also requires federal agencies to consider the reason for low prices in European countries. Trump said he would use commercial policy to make these countries pay more. However, since drug makers have already contracts with these governments, it is not clear how this will be applied.

According to pharmaceutical companies, high prices in the United States allow people to obtain their prescriptions faster and with fewer insurance restrictions.

John F. said. Crowley, CEO of The Biotechnology Innovation, at A Cornerstone in the Driving of Biotechnology in America, the same companies are the leading companies in the field of medical innovation in the field of biotechnology, “Most of the favorite nation is a very defective proposal that will destroy small and medium -sized biotechnology companies, which are the same companies are the leading engines in the field of innovation Medical in the United States and organizing the foundation stone in the field of biotechnology in America. ” statement.

On the other hand, the Times newspaper reported that Stephen J. UBL, CEO of Perma, an American commercial group representing pharmaceutical companies, stated that “American patients should not restrict the global innovation bill”, and that foreign governments must “push their fair share of medicines.”

The time will only determine how and if this executive matter is enacted and whether American pharmaceutical companies will voluntarily reduce their prices for American patients. Meanwhile, we will wait for Trump pharmacies The tariff announcement.